Bb5a31f81ClaimIn a clinical trial conducted through UC San Diego and UCLA, co-administration of Agarikon and Turkey Tail mycelium with COVID-19 mRNA vaccines statistically significantly reduced adverse reactionsAgreeDisagree
Bb5a31f81ClaimA ketogenic dietary intervention studied by Virta Health reversed type 2 diabetes in 60 percent of participating patientsAgreeDisagree
Bb5a31f81ClaimThe Women's Health Initiative clinical trial evaluating hormone replacement therapy revealed that prior observational studies were confounded by healthy user biasAgreeDisagree
Bb5a31f81ClaimPatients treated with Merck and Moderna's experimental melanoma vaccine were less likely to develop distant metastatic recurrence than untreated trial participantsAgreeDisagree
Bb5a31f81ClaimIn psilocybin mushroom clinical trials, a standard therapeutic dose is commonly established at 25 milligrams of psilocybin or approximately 2.5 grams of dried Psilocybe cubensisAgreeDisagree
Bb5a31f81ClaimClinical trials conducted by Compass Pathways showed an approximately 40 to 45 percent response rate for psilocybin therapy in treatment-resistant depressionAgreeDisagree
Bb5a31f81ClaimClinical trial data over two years showed patients receiving Merck and Moderna's experimental melanoma vaccine were 42 percent less likely to experience cancer recurrence compared to patients who did not receive the vaccineAgreeDisagree
Bb5a31f81ClaimA clinical trial for Merck and Moderna's experimental melanoma vaccine enrolled more than 1,100 patients with stage 2, stage 3, or stage 4 melanomaAgreeDisagree
Bb5a31f81ClaimPatients who received Merck and Moderna's experimental melanoma vaccine reported mild side effects consisting of sore arms and flu-like symptoms lasting one to two daysAgreeDisagree
Bb5a31f81ClaimIn symptomatic, unvaccinated COVID-19 patients, treatment with Agarikon and Turkey Tail mycelium was associated with symptom resolution 5.1 days faster than placeboAgreeDisagree
Bb5a31f81ClaimPatients participating in Merck and Moderna's experimental melanoma vaccine clinical trial received nine doses administered once every three weeksAgreeDisagree
Bb5a31f81ClaimMerck and Moderna's experimental melanoma vaccine was administered to clinical trial patients in combination with an immune checkpoint inhibitor drugAgreeDisagree
Bb5a31f81ClaimClinical trials demonstrate that patients taking SGLT2 inhibitors lose an average of five to eight poundsAgreeDisagree
Bb5a31f81ClaimHenagliflozin treatment in a 26-week trial increased levels of Granzyme B in immune killer T cellsAgreeDisagree
Bb5a31f81ClaimIn a 26-week henagliflozin trial, 90% of patients taking henagliflozin gained telomere length compared to 66% of patients receiving placeboAgreeDisagree
Bb5a31f81ClaimParticipants taking henagliflozin in a Cell Reports Medicine trial experienced significant reductions in serum uric acid compared to placeboAgreeDisagree
Bb5a31f81ClaimHenagliflozin treatment in a 26-week trial increased insulin-like growth factor-binding protein levels relative to placeboAgreeDisagree
Bb5a31f81ClaimCardiovascular risk reduction in the 2015 EMPA-REG trial occurred independently of changes in blood glucose levelsAgreeDisagree
Bb5a31f81ClaimThe cardiovascular mortality reduction observed in the 2015 EMPA-REG trial emerged within months of initiating SGLT2 inhibitor treatmentAgreeDisagree
Bb5a31f81ClaimThe average age of type 2 diabetes participants in the 26-week henagliflozin trial published in Cell Reports Medicine was 52 yearsAgreeDisagree